Open AccessDon’t forget ototoxicity during the SARS-CoV-2 (Covid-19) pandemic!
Author(s) -
Andrea Ciorba,
Virginia Corazzi,
Piotr H. Skarżyński,
Magdalena B. Skarżyńska,
Chiara Bianchini,
Stefano Pelucchi,
Stavros Hatzopoulos
Publication year - 2020
Publication title -
international journal of immunopathology and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.724
H-Index - 53
eISSN - 2058-7384
pISSN - 0394-6320
DOI - 10.1177/2058738420941754
Subject(s) - hydroxychloroquine , favipiravir , azithromycin , covid-19 , medicine , lopinavir , pandemic , chloroquine , ototoxicity , lopinavir/ritonavir , virology , intensive care medicine , immunology , outbreak , biology , disease , malaria , antibiotics , cisplatin , chemotherapy , infectious disease (medical specialty) , microbiology and biotechnology
Aim of this communication is to remind clinical professionals to be aware of ototoxic side effects of several specific drugs proposed for the treatment of the new virus SARS-CoV-2 (Covid-19). In particular, chloroquine and hydroxychloroquine, azithromycin, as well as antiviral drugs such as remdesivir, favipiravir and lopinavir can all present potential ototoxic side effects. The data in the literature do not offer specific information on their potential synergetic effects nor on their interactions.